



Children and Young Person's Diabetes Network Wales Teplizumab Pathway

Following NICE approval for use of the biologic teplizumab, the following pathway has been developed by the CYPDNW for use in all health boards in Wales. This represents the agreed collaborative effort of clinicians delivering paediatric diabetes care from a multidisciplinary meeting and subsequent feedback sought using the CYPDNW governance pathway.

The pathway is for use in children older than 8 years of age, identified to be in Early type 1 diabetes. It aims to provide a systematic, psychologically supported care pathway, with patient and family education embedded throughout the process.

Patients who have been identified that may benefit from teplizumab using the BSPED guidance, will be managed within each health board to ensure equity of access and provide poverty-proofing.

Education for the pathway will link into the current SEREN education package for type 1 diabetes, alongside literature developed to support the discussion of early type 1 diabetes with families. The Early Type 1 SEREN package will be used to facilitate family discussion, including what is diabetes, healthy eating and activity, and the use of teplizumab.

Each health board will identify a location for the infusion; HDU admission should be considered for the duration of the infusion. Each health board will identify the team to deliver the infusion, but most likely will be registered children's nurses on the paediatric ward.

Adverse Drug Events (ADEs) should be reported using normal processes

After the last infusion a Post-infusion review by the diabetes team will be undertaken; further follow-up will be 3-6 monthly.



Appendix 1: CYPD Network Wales Teplizumab Pathway

